GENTAMICIN SULFATE ophthalmic solution, USP 0.3% sterile

Manufacturer
Aidarex Pharmaceuticals LLC
Effective date
2014-01-03
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:17:45

Label at a glance#

ProductGENTAMICIN SULFATE
Active ingredientGENTAMICIN SULFATE
Label structure10 sections

Indications and uses

Gentamicin sulfate ophthalmic solution, USP is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus...

Dosage and administration

Instill one or two drops into the affected eye(s) every four hours. In severe infections, dosage may be increased to as much as two drops every hour.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Gentamicin sulfate ophthalmic solution, USP is a sterile, topical anti-infective agent for ophthalmic use.

Gentamicin is obtained from cultures of Micromonospora purpurea. It is a mixture of the sulfate salts of gentamicin C1, C2, and C1A. All three components appear to have similar antimicrobial activity. Gentamicin sulfate occurs as a white to buff powder and is soluble in water and insoluble in alcohol. The structural formula is as follows:

Structural Formula
Structural Formula

Each mL contains: Active: gentamicin sulfate equivalent to 3 mg (0.3%) gentamicin base. Preservative: benzalkonium chloride. Inactives: edetate disodium; polyvinyl alcohol 1.4%; purified water; sodium chloride; sodium phosphate, dibasic; and hydrochloric acid and/or sodium hydroxide may be added to adjust pH. The solution is an aqueous, buffered solution with a shelf life pH range of 6.5 to 7.5.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Microbiology

MICROBIOLOGY SECTION

Gentamicin sulfate is active in vitro against many strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Gentamicin sulfate ophthalmic solution, USP is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Gentamicin sulfate ophthalmic solution, USP is contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS

WARNINGS SECTION

NOT FOR INJECTION INTO THE EYE.

Gentamicin sulfate ophthalmic solution, USP is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Prolonged use of topical antibiotics may give rise to overgrowth of nonsusceptible microorganisms, including fungi. Bacterial resistance to gentamicin may also develop. If purulent discharge, inflammation or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician.

If irritation or hypersensitivity to any component of the drug develops, the patient should discontinue use of this preparation and appropriate therapy should be instituted.

Information for Patients

INFORMATION FOR PATIENTS SECTION

To avoid contamination, do not touch tip of container to the eye, eyelid or any surface.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

There are no published carcinogenicity or impairment of fertility studies on gentamicin. Aminoglycoside antibiotics have been found to be non-mutagenic.

Pregnancy

PREGNANCY SECTION

SPL UNCLASSIFIED SECTION

Pregnancy Category C

Gentamicin has been shown to depress body weights, kidney weights and median glomerular counts in newborn rats when administered systemically to pregnant rats in daily doses approximately 500 times the maximum recommended ophthalmic human dose. There are no adequate and well-controlled studies in pregnant women. Gentamicin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in neonates have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations.

The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects and conjunctival hyperemia.

Other adverse reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura and hallucinations.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Instill one or two drops into the affected eye(s) every four hours. In severe infections, dosage may be increased to as much as two drops every hour.

HOW SUPPLIED

HOW SUPPLIED SECTION

Gentamicin sulfate ophthalmic solution, USP 0.3% is supplied sterile in white opaque LDPE plastic bottles and tips with white high impact polystyrene (HIPS) caps as follows:

  •              5 mL – NDC 33261-0604-01

Storage: Store at or below 25°C (77°F). Avoid exposure to excessive heat (40°C/104°F or above).

Revised: 08/2013

© 2013 Allergan, Inc.
Irvine, CA 92612, U.S.A.
® mark owned by Allergan, Inc.
Made in the U.S.A.

LogoLogo

Repackaged By :
Aidarex Pharmaceuticals LLC,
Corona, CA 92880

71759PY11

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 33261-0604-01

GENTAMICIN
SULFATE
ophthalmic
solution, USP
0.3%

5 mL

sterile

Rx only

IMAGE LABELIMAGE LABEL

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
310467gentamicin sulfate 0.3 % Ophthalmic SolutionPSN1
310467gentamicin 3 MG/ML Ophthalmic SolutionSCD1
310467gentamicin (as gentamicin sulfate) 0.3 % Ophthalmic SolutionSY1
310467gentamicin sulfate 3 MG/ML Ophthalmic SolutionSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
GENTAMICIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
3b7b3a7a-635f-32a3-0c6c-7ad028e3de91Product name220250107
43025f0d-698c-68da-cec9-ea4261a7ef7aProduct name220250107
d3946667-8212-d1f2-67e1-5643a329bb56Product name220200403
4ce5dce5-e8a7-e4f6-0059-b527e4307477Product name220190501
48b05f5d-d2fc-45ab-76e8-3cb5bd44890dProduct name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
33261-604-012020-01-31C16284748780-19d75b9cf-f1a6-f424-e053-dadaa90a57ceGENTAMICIN SULFATE ophthalmic solution, USP 0.3% sterile

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
33261-604-01GENTAMICIN SULFATE1 in 1 CARTONSOLUTION/ DROPS11
33261-604-01GENTAMICIN SULFATE5 mL in 1 BOTTLE, DROPPERSOLUTION/ DROPS51

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
33261-604GENTAMICIN SULFATE SOLUTION/ DROPS [AIDAREX PHARMACEUTICALS LLC]1Legacy NDC, 2 package rows20140110_2e647e36-15d9-49e9-b81b-35465441e37a.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
33261-604-01ML - Milliliter33261-60450aa3506-8c67-46c6-af07-db81b8be108912015-10-02
60758-188-05ML - Milliliter60758-188d155d9ac-d56c-4938-a7d3-39ee324dd1f512012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
GENTAMICIN SULFATEACTIVE INGREDIENT8X7386QRLV1
GENTAMICINACTIVE MOIETYT6Z9V48IKG1
BENZALKONIUM CHLORIDEINACTIVE INGREDIENTF5UM2KM3W71
EDETATE DISODIUMINACTIVE INGREDIENT7FLD91C86K1
HYDROCHLORIC ACIDINACTIVE INGREDIENTQTT17582CB1
POLYVINYL ALCOHOLINACTIVE INGREDIENT532B59J9901
SODIUM CHLORIDEINACTIVE INGREDIENT451W47IQ8X1
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32I1
SODIUM PHOSPHATE, DIBASICINACTIVE INGREDIENTGR686LBA741
WATERINACTIVE INGREDIENT059QF0KO0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 10 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
33261-60433261-604-01
60758-188

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 10 · 588 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IGEL / TRANSDERMAL472 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION / INTRAVENOUS28773 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARYADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRADERMALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IPOWDER, FOR SUSPENSION / ORAL9 mgExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSOLUTION / INTRAMUSCULARADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRA-ARTICULARADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / INTRAMUSCULAR1037 mgExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM PHOSPHATE, DIBASICSODIUM PHOSPHATE, DIBASICGR686LBA74INJECTION / INTRAMUSCULAR40 mgExact identifier — unii candidate
14 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / INTRATUMORADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM PHOSPHATE, DIBASICSODIUM PHOSPHATE, DIBASICGR686LBA74FILM, SOLUBLE / ORAL9 mgExact identifier — unii candidate
14 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSPRAY / RESPIRATORY (INHALATION)0.05 %w/wExact identifier — unii candidate
77 equally ranked IID candidates
BENZALKONIUM CHLORIDEBENZALKONIUM CHLORIDEF5UM2KM3W7CLOTH / TOPICALNAExact identifier — unii candidate
24 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRAVENOUS720 mgExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRAVITREALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION, CONCENTRATE / INTRAVENOUS69 mgExact identifier — unii candidate
134 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSOLUTION / RESPIRATORY (INHALATION)43 mgExact identifier — unii candidate
77 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRA-AMNIOTICADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
POLYVINYL ALCOHOLPOLYVINYL ALCOHOL532B59J990TABLET, COATED / ORAL0.7 mgExact identifier — unii candidate
17 equally ranked IID candidates
POLYVINYL ALCOHOLPOLYVINYL ALCOHOL532B59J990SOLUTION / OPHTHALMIC6 mgExact identifier — unii candidate
17 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRAVENOUS456 mgExact identifier — unii candidate
174 equally ranked IID candidates
BENZALKONIUM CHLORIDEBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / RESPIRATORY (INHALATION)0.02 %w/wExact identifier — unii candidate
24 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION / INTRABURSAL0.01 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IMOUTHWASH / BUCCAL2 mg/1mlExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTABLE, LIPOSOMAL / INTRAVENOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KGEL / VAGINAL5 mgExact identifier — unii candidate
77 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRASYNOVIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBMUCOSAL16 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
BENZALKONIUM CHLORIDEBENZALKONIUM CHLORIDEF5UM2KM3W7INJECTION / INTRAMUSCULAR1 mgExact identifier — unii candidate
24 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SUSPENSION / INTRASYNOVIAL4 mgExact identifier — unii candidate
134 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KCAPSULE / ORAL5 mgExact identifier — unii candidate
77 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INFILTRATIONADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBAEROSOL, METERED / RESPIRATORY (INHALATION)0.7 %w/wExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XENEMA / RECTAL0.7 %w/wExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XLIQUID / SUBCUTANEOUS0.7 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTERSTITIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XPOWDER, FOR SOLUTION / OPHTHALMIC0.9 %w/wExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISPRAY, METERED / NASALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / INTRADISCALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION / EPIDURAL648 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XGRANULE, FOR SUSPENSION / ORAL162 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSOLUTION / NASAL330 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION / AURICULAR (OTIC)ADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / RESPIRATORY (INHALATION)8 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XGEL / VAGINAL10 %w/wExact identifier — unii candidate
134 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVERNOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XTABLET, CHEWABLE / ORAL20 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IGRANULE, FOR SUSPENSION / ORALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBPOWDER, FOR SUSPENSION / ORAL125 mgExact identifier — unii candidate
148 equally ranked IID candidates
BENZALKONIUM CHLORIDEBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION/ DROPS / OPHTHALMIC1 mgExact identifier — unii candidate
24 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KTABLET, EFFERVESCENT / ORAL32 mgExact identifier — unii candidate
77 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION / INTRA-ARTICULAR26 mgExact identifier — unii candidate
134 equally ranked IID candidates
POLYVINYL ALCOHOLPOLYVINYL ALCOHOL532B59J990CREAM / VAGINAL0.5 %w/wExact identifier — unii candidate
17 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRALESIONALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IJELLY / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRASYNOVIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / RETROBULBARADJ PHExact identifier — unii candidate
148 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A062452-001GENOPTICGENTAMICIN SULFATEEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10d4dbc9d85df4…
2026-10-15 13:18:302026-09A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10c2088c7a36db…
2026-09-14 22:38:342026-08A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-1084e616aacf4f…
2026-08-18 06:07:402026-07A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-1031067a03dcf5…
2025-08-23 18:47 UTC2025-08A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-106a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-1003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-102680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-105bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-1079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-101e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-108072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-105c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-105d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-104b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-1074a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-10bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-10782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-1087673890dc5c…
2021-03-12 10:30 UTC2021-03A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-105aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-108869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-10c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-103f01610625f2…
2019-09-15 20:21 UTC2019-09A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-10b00525d2431f…
2019-07-19 19:46 UTC2019-07A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-10ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-106a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-101c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-109b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-103f0d92c62455…
2023-05-13 08:27 UTC2023-05A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10053a50430f4f…
2023-01-26 05:58 UTC2023-01A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-103bdfa0b2c4d7…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062452-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062452-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062452-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062452-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062452-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062452-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062452-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A062452-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062452-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062452-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062452-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A062452-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A062452-001AT1ea99ee380514…
2023-01-26 05:58 UTC2023-01A062452-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062452-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062452-001AT1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A062452-001AT1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A062452-001AT1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
2323a0e0-63f8-4083-bda3-2f65f374fd402e647e36-15d9-49e9-b81b-35465441e37a2014-01-03Warnings, Adverse reactionsExact identifier
spl id: 2323a0e0-63f8-4083-bda3-2f65f374fd40
spl set id: 2e647e36-15d9-49e9-b81b-35465441e37a

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.